Preformed Line Products
PLPC
92 hedge funds and large institutions have $148M invested in Preformed Line Products in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
15% more capital invested
Capital invested by funds: $129M → $148M (+$19.2M)
14% more funds holding
Funds holding: 81 → 92 (+11)
0.28% less ownership
Funds ownership: 42.48% → 42.2% (-0.28%)
Top Buyers
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$1.78M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.37M |
| 3 |
Walleye Capital
New York
|
+$489K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$433K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$423K |
Top Sellers
PLPC Hedge Fund Activity: Q3 2022 in Review
92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Preformed Line Products (PLPC) for Q3 2022, worth a combined $148M — up 15% from $129M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PLPC positions and 4 closed out — a net gain of 11 holders — while 36 added to existing stakes and 23 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.78M. The largest seller was Invenomic Capital Management, exiting entirely with an estimated $1.94M sold.
- 92 institutional investors held Preformed Line Products (PLPC) as of Q3 2022, up from 81 in Q2 2022.
- Funds reported $148M of Preformed Line Products stock for Q3 2022, up 15% quarter-over-quarter.
- 15 funds opened new Preformed Line Products positions in Q3 2022 and 4 closed out, a net change of +11 holders.
- The largest Preformed Line Products buyer in Q3 2022 was EAM Investors, an estimated $1.78M added.
- The largest Preformed Line Products seller in Q3 2022 was Invenomic Capital Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2022.